Memantine HCl
NMDA antagonist / Anti-Alzheimer's / An NMDA noncompetitive, low affinity, open channel blocker, IC50~1 μM at -60 mV in rat retinal ganglion cells.1 Displays neuroprotective effects in excitotoxic conditions.2 Preferentially blocks excessive NMDA receptor activity without disrupting normal activity.3 A clinically well tolerated drug with therapeutic potential in numerous CNS degenerative disorders.4 In clinical use for Alzheimer’s disease.5
Biochemicals & reagents
41100-52-1
3,5-Dimethyl-tricyclo[3.3.1.13,7]decam-1-amine HCl
1) Chen and Lipton (1997), Mechanism of memantine block of NMDA-activated channels in rat retinal ganglion cells: uncompetitive antagonism; J. Physiol. 499 27 2) Chen et al. (1998), Neuroprotective concentrations of the N-methyl-D-aspartate open-channel blocker memantine are effective without cytoplasmic vacuolation following post-ischemic administration and do not block maze learning or long-term poptentiation; Neuroscience 86 1121 3) Lipton et al. (2005), the molecular basis of memantine action in Alzheimer’s disease and other neurologic disorders: low-affinity, uncompetitive antagonism; Curr. Alzheimer. Res. 2 155 4) Parsons et al. (1999), Memantine is a clinicall well tolerated N-methyl-D-aspartate (NMDA) receptor antagonist—a review of preclinical data; Neuropharmacology 38 735 5) Witt et al. (2004), Memantine hydrochloride; Nat. Rev. Drug Discov. 3 109
RT
TARGET: Ion channel -- PATHWAY: Cation channel -- RESEARCH AREA: Neuroscience -- DISEASE AREA: Neurodegeneration